VERU Quote, Financials, Valuation and Earnings

Bioage Labs has a net margin of -128.15% compared to Veru's net margin of --. Veru's return on equity of -101.38% beat Bioage Labs's return on equity of --.

Veru has a consensus price target of $3.40, signalling upside risk potential of 396.64%. On the other hand Bioage Labs has an analysts' consensus of -- which suggests that it could grow by 7.71%. Given that Veru has higher upside potential than Bioage Labs, analysts believe Veru is more attractive than Bioage Labs.

Veru has a beta of -0.500, which suggesting that the stock is 150.04% less volatile than S&P 500. In comparison Bioage Labs has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bioage Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Bioage Labs pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Bioage Labs quarterly revenues of --. Veru's net income of -$8.5M is higher than Bioage Labs's net income of -$13.6M. Notably, Veru's price-to-earnings ratio is -- while Bioage Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 5.47x versus -- for Bioage Labs. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics has a net margin of -128.15% compared to Veru's net margin of -13648.45%. Veru's return on equity of -101.38% beat Keros Therapeutics's return on equity of -44.6%.

Veru has a consensus price target of $3.40, signalling upside risk potential of 396.64%. On the other hand Keros Therapeutics has an analysts' consensus of $43.55 which suggests that it could grow by 159.05%. Given that Veru has higher upside potential than Keros Therapeutics, analysts believe Veru is more attractive than Keros Therapeutics.

Veru has a beta of -0.500, which suggesting that the stock is 150.04% less volatile than S&P 500. In comparison Keros Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Keros Therapeutics pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Keros Therapeutics quarterly revenues of $388K. Veru's net income of -$8.5M is higher than Keros Therapeutics's net income of -$53M. Notably, Veru's price-to-earnings ratio is -- while Keros Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 5.47x versus 900.62x for Keros Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -128.15% compared to Veru's net margin of 36.03%. Veru's return on equity of -101.38% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Veru has a consensus price target of $3.40, signalling upside risk potential of 396.64%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 46.94%. Given that Veru has higher upside potential than Regeneron Pharmaceuticals, analysts believe Veru is more attractive than Regeneron Pharmaceuticals.

Veru has a beta of -0.500, which suggesting that the stock is 150.04% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Veru's net income of -$8.5M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Veru's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 5.47x versus 5.96x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -128.15% compared to Veru's net margin of --. Veru's return on equity of -101.38% beat Scholar Rock Holding's return on equity of --.

Veru has a consensus price target of $3.40, signalling upside risk potential of 396.64%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 1.41%. Given that Veru has higher upside potential than Scholar Rock Holding, analysts believe Veru is more attractive than Scholar Rock Holding.

Veru has a beta of -0.500, which suggesting that the stock is 150.04% less volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.249%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Scholar Rock Holding quarterly revenues of --. Veru's net income of -$8.5M is higher than Scholar Rock Holding's net income of -$64.5M. Notably, Veru's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 5.47x versus 92.52x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.